TGFB1 and neoplasm: Nevertheless, combined GARP:TGF-β1/PD-1 blockade increased immune-mediated tumor rejections to a similar extent in CT26 and MC38 tumors (8), indicating that both modes of action can significantly contribute to the anti-tumor activity of the combination.